source
- Braveheart, Attovia join next wave of biotech IPOsThe two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.BioPharma Dive · 15d ago↗ source
- Radiopharma maker AdvanCell hauls in $315M for Pluvicto challengerAdvanCell raised a $315 million Series D to study a lead-based prostate cancer agent and shore up its US manufacturing of the radioactive treatment. The round marks one of the largest yet for a rad…Endpoints · 15d ago↗ source
- J&J touts Icotyde prescriptions, but not sales, in first full quarterJohnson & Johnson teased some details on Wednesday morning about how the launch of its expected blockbuster Icotyde performed in the second quarter. Without disclosing how much revenue the plaque p…